Simulations Plus Positioned to Capitalize on FDA's Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration's draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokinetic.

Business Wire • Dec 9, 2025

3 Software Stocks to Watch as the Industry Gains Momentum

Steady digital transformation and strong adoption of AI bode well for Computer Software industry participants like SNPS, DSGX and SLP amid broader market volatility.

Zacks Investment Research • Dec 9, 2025

Why Shares of Simulations Plus Soared This Week

Shares of Simulations Plus had gained more than 20% as of midday Thursday. The company reported mixed results, but its guidance calls for revenue and earnings growth in fiscal 2026 despite a difficult environment.

The Motley Fool • Dec 4, 2025

Simulations Plus Stock Climbs On Earnings Strength, Biotech Market Rebound

Simulations Plus Inc. (NASDAQ: SLP) shares climbed on Tuesday after the company reported better-than-expected fourth-quarter 2025 earnings and reaffirmed annual guidance.

Benzinga • Dec 2, 2025

Why Simulations Plus Stock Was Soaring Today

Its full-year fiscal 2025 featured a double-digit revenue increase. As for the fourth quarter, its performance was mixed.

The Motley Fool • Dec 2, 2025

Simulations Plus' Q4 Earnings & Sales Meet Estimates, Fall Y/Y

SLP posts softer fiscal Q4 2025 results but meets full-year goals as cloud, AI and integrated workflows shape its next growth phase.

Zacks Investment Research • Dec 2, 2025

Simulations Plus: Buying On Long-Term Silico Drug-Development

Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP's services help across discovery, development, and clinical operations. Software remains their main economic driver with higher margins. Services are growing faster and gradually increasing their share of total revenues but have lower margins.

Seeking Alpha • Dec 3, 2025

Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript

Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript

Seeking Alpha • Dec 2, 2025

Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software rev.

Business Wire • Dec 1, 2025

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Simulations Plus, Inc. (NASDAQ: SLP) and Encourages Investors with Substantial Losses to Contact the Firm

NEWTOWN, Pa. , Nov. 28, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public.

PRNewsWire • Nov 28, 2025